QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • NewCardio (NWCI) Chosen to Provide QTinno Technology by Major Pharmaceutical Company 1 comment
    Mar 17, 2011 4:36 PM

    NewCario Inc., a cardiovascular diagnostic solutions developer, today announced that a Top 5 global pharmaceutical company has selected NewCardio’s QTinno® automated cardiac safety solution for two phase I drug safety studies slated to begin in March.

    The QTinno 3-D ECG software technology is designed to assess drug cardiac toxicity in drug development. The company anticipates that pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno’s faster, more accurate and less expensive assessment of cardiac status.

    In accordance with the terms of an existing Master Services Agreement, NewCardio’s QTinno-powered, fully automated ECG analysis will be delivered by the ECG core lab of a Top 3 Clinical Research Organization (CRO).

    NewCardio said the unnamed pharmaceutical company selected QTinno based on its proven ability to enable the CRO to deliver high-quality results in a much more timely and cost effective manner than the current core ECG lab methodologies. Turnaround time was also a critical deciding factor, as the sponsor needs to present the results to the FDA for review after part 1 of the initial study in order to develop the requirements for part 2 of the study.

    “We are excited to participate in these important studies, and gratified that a major global pharmaceutical company specifically identified QTinno for automated analysis of all the ECGs from the studies. QTinno’s selection for these studies provides clear evidence of the pharmaceutical company’s confidence, not only in the accuracy and precision of QTinno’s fully automated ECG analysis, but also in the FDA’s willingness to accept drug safety data from properly validated technology such as QTinno. We expect that QTinno will play an increasingly important role as the drug development industry accelerates their adoption of the higher quality, cost effective cardiac safety analysis,” Vincent Renz, NewCardio president and CEO stated in the press release.

    Renz said NewCardio’s business model allows the company to work with various industry players rather than competing with them.

    “This selection represents further evidence of the increasing market adoption of QTinno, not only as a validated methodology, but also as a clear leader in delivering advanced technology solutions for the drug development industry,” Renz continued. “Our business model as a technology developer, not an ECG core lab, enables us to work effectively with all of our customers and partners as we are not competing with them but rather equipping them with solutions and enabling them to deliver enhanced clinical trial products and services. We are pleased that industry leaders are embracing QTinno, and we look forward to an accelerating adoption cycle with increasing market penetration,” Renz stated.

    The studies are expected to be completed by June 2011; NewCardio expects to recognize revenue from the studies in the first half of 2011.

    For more information visit newcardio.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • deeppocketsgolf
    , contributor
    Comments (111) | Send Message
    NWCI, NewCardio: Recently presented @ The Wells Fargo Securities Healthcare Conference;


    Which gave it a 8 Cent boost; from 25 Cents;[2.599M Market Cap]


    Per Equity @ 32 Cents; Recent Quarterly Report;


    Report Category, ,Notes, Report, Price, , Metric, , Weight, , Primary Weight Adj Trading Metric, ,Year / Desig/ DAY Weight Adj Price.


    20. Deficit, (45) ,M, 10-Q 0.32 , (0.23) , 0.9063 , (0.21) ,July 2011, 0.29


    21. Paid In Equity, 40 ,M, 10-Q 0.32 , 0.26 , 0.7813 , 0.20 ,July 2011, 0.25


    22. Preferred, 0.000015 ,M, 10-Q 0.32 , 693019 , 1.015 , 703,629 ,July 2011, 0.32


    23. Common Stk Amt, 0.0308 ,M, 10-Q 0.32 , 337 , 1.000 , 337 ,July 2011, 0.32


    24. Other Inc or Loss 0.00 ,M, 10-Q 0.32 , 0.00 , 1.0313 , 0 ,July 2011, 0.33


    Sum Trading At: ,Primary Metric per Equity: ($4.428) M, 693,356 ,Metric Weighted per Price Range / Change, 4.73_404 ,Combined Weight Adj Trade Metric, 703,966.1_15_8_86_404 ,for +$0.553M Market Cap, for, 0.017 on adjusted level price of .303;


    Estimate of Forward Activity:


    Equity $$MM: (4.428)
    MinRetGrowth: 0.03
    MinRetInv: 0.05
    Weighted Cost of Capital: 92.47%
    Estimated Local Continuing Value in $$M: (1.992072)
    Estimated Factor NOT LOCAL in $$M: 4.824,522M
    Estimated ContinuingValue :In Line With R&D Expense Annualized MRQ / Net Loss ttm$$M: (9.610,792)
    Est NOT LOCAL Price / 5.24M Market Cap : 0.16_12_22
    (0.2959) ,Factor Forward.
    (0.54494) ,Not Local Price To.


    Current Market Cap 10.72M; Off the high of $1.15_66_19


    News / Recent Presentation's.
    NewCardio Selected to Present at Wells Fargo Securities Healthcare Conference.


    NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society.


    NewCardio Selected to present @ the Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City.


    NewCardio Selected to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development.


    About NewCardio, Inc.


    NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-Lead 3D ECG.
    NewCardio's 3D ECG technology software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.
    NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development.
    For more information, visit newcardio.com.


    Quote:Enter NWCI and Get Info @:




    2008:4.32 / Share;


    Do not own Shares of NWCI, Review the Company; Looking for 16.22 Cents with Volume; Volume YTD: 5M Shares;
    8 Jul 2011, 08:03 AM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.